You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Alliance Pharma plc ("Alliance" or the "Company"), the speciality pharmaceutical company, is pleased to announce the appointment of David Cook as an independent Non-executive Director of the Company, effective 1 April 2014.

David is currently Chief Financial Officer and Chief Business Officer of Biotie Therapies Inc, a drug development company quoted in Helsinki on the NASDAQ OMX market. He has previously held senior financial positions with Jazz Pharmaceuticals Limited, EUSA Pharma Inc and Cephalon Inc.

David qualified as a chartered accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford. It is intended that he will be appointed Chair of Alliance's Audit Committee on the retirement of Michael Gatenby.

“We welcome David to the Board of Alliance. His extensive knowledge and experience of the pharmaceutical industry makes him a strong addition to the Board. His particular career focus on acquisitions and finance should provide valuable insights to support the Company's strategy”

Michael Gatenby, Chairman of Alliance

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. David John Cook, age 46 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships
Biotie Therapies Inc

Past directorships
EUSA Pharma SAS
EUSA Pharma Holding SAS
EUSA Pharma (Europe) Limited
EUSA Pharma (Europe) UK Limited
EUSA Pharma (UK) Limited
EUSA Pharma Limited
Orphan Pharma International Limited
EUSA Pharma BV
EUSA Pharma GmbH
EUSA Pharma (Gibraltar) Limited
EUSA Pharma (USA) Inc. (now called Jazz Pharmaceuticals (EUSA Pharma USA) Inc.)
Prostagen, Inc.
Cytogen Acquisition Corp.
AxCell Biosciences Corporation

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

FOR FURTHER INFORMATION:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.